Posted by Michael Wonder on 26 May 2022
NICE recommends Libtayo (cemiplimab) for routine NHS commissioning as the first and only systemic treatment for advanced CSCC in England
25 May 2022 - NICE has published a positive Final Appraisal Determination recommending Libtayo (cemiplimab) as the first and only systemic treatment option in England for metastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiation is not appropriate.
This means eligible patients will have full NHS access in England via routine commissioning.
